Contact: |
Trinity Biotech plc
|
Lytham Partners, LLC
|
John Gillard
|
Joe Diaz
|
|
(353)-1-2769800
|
(1)-602-889-9700
|
|
E-mail: investorrelations@trinitybiotech.com |
1. |
An ordinary resolution to increase the Company’s authorised share capital by the creation of an additional 600,000,000 A ordinary shares of US$0.0109 each.
|
2. |
An ordinary resolution to authorise the board of directors to reappoint Grant Thornton as the Company’s statutory auditors.
|
3. |
An ordinary resolution to authorise the board of directors to fix the statutory auditors’ remuneration.
|
4. |
Re-election of directors:
|
a. |
An ordinary resolution to re-elect as a director Mr. Aris Kekedjian who retires by rotation and, being eligible, offers himself for re-election.
|
b. |
An ordinary resolution to re-elect as a director Mr. Michael Sung Soo Kim who retires by rotation and, being eligible, offers himself for re-election.
|
c. |
An ordinary resolution to re-elect as a director Mr. Seon Kyu Jeon who retires by rotation and, being eligible, offers himself for re-election.
|
5. |
An ordinary resolution to review the affairs of the Company and consider the financial statements of the Company for the year ended December 31, 2021 together with
the reports of the directors and statutory auditors thereon.
|
6. |
A special resolution to alter the Memorandum of Association of the Company.
|
7. |
A special resolution to adopt new Articles of Association of the Company to take account of certain changes to Irish company law resulting from the Companies Act 2014
(the "Act") and certain related developments.
|
8. |
A special resolution to renew the authority for the Company and/or any of its subsidiaries to purchase the Company's own shares and American Depositary Receipts
evidencing such shares ("ADRs") on NASDAQ within certain prescribed limits.
|